Ongoing research

There are currently the following ongoing research programmes into Barrett’s Oesophagus:

      • A collaborative study between UKBOR (UK Barrett's Oesophagus Registry) & Harvard University
      • A study to identify Barrett’s Oesophagus susceptibility genes, funded by the Association for International Cancer Research

Aspirin & Barrett's Oesophagus

Treatment of Barrett’s Oesophagus using common aspirin is discussed in the European Journal of Cancer.

Please see: Aspirin is not chemoprotective for Barrett's Adenocarcinoma of the oesophagus in multicentre cohort, PA Gatenby, JR Ramus, CP Caygill, MC Winslet, A Watson, European Journal Cancer, Volume 18, no 5 September 09, pp381-4.

New data on Barrx RF Ablation (formerly HALO RFT or RF ablation)

Patients with dysplastic Barrett's Oesophagus who were treated with radiofrequency ablation were more likely to have complete eradication of dysplasia and intestinal metaplasia and less likely to progress to more severe dysplasia or cancer, a study published in New England Journal found.

Currently Barrx RF Ablation is offered in more than 30 hospitals in the UK (April 2015).

You can acquire more information from Covidien or Medtronic websites or direct from Barrx here.